Order Article Reprints

McElree IM, Packiam VT, Steinberg RL, Hougen HY, Mott SL, Abou Chakra M, Zakharia Y, O’Donnell MA. Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor. Cancers. 2024; 16(14):2561. https://doi.org/10.3390/cancers16142561

McElree, Ian M., Vignesh T. Packiam, Ryan L. Steinberg, Helen Y. Hougen, Sarah L. Mott, Mohamad Abou Chakra, Yousef Zakharia, and Michael A. O’Donnell. 2024. "Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor" Cancers 16, no. 14: 2561. https://doi.org/10.3390/cancers16142561

McElree, I. M., Packiam, V. T., Steinberg, R. L., Hougen, H. Y., Mott, S. L., Abou Chakra, M., Zakharia, Y., & O’Donnell, M. A. (2024). Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor. Cancers, 16(14), 2561. https://doi.org/10.3390/cancers16142561